Clinical trials: Cytokine Release Syndrome
Infection After Transfusion, Transfusion-related Immunomodulation Reaction
Blood Transfusions and Immune Response
We have previously reported the results of the primary and secondary outcomes of a randomized study aiming to investigate the impact of a restrictive transfusion protocol on the magnitude of reduction in blood transfusion in a…
- Conditions
- Infection After Transfusion, Transfusion-related Immunomodulation Reaction, Cytokine Storm, Surgery
- Trial name
- NCT02020525
- Testing
- restrictive transfusion strategy, liberal transfusion strategy
- Where
- Greece
- Volunteers
- 58 people
- Sponsor
- Aretaieion University Hospital
COVID, SARS Pneumonia
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
The trial evaluates the efficacy and safety of Tocilizumab, which rapidly reduces the inflammation process through inhibition of IL-6 in patients with moderate to severe COVID-19 with increased inflammatory markers.
- Conditions
- COVID, SARS Pneumonia, Cytokine Release Syndrome
- Trial name
- TOCIBRAS (NCT04403685)
- Testing
- Tocilizumab
- Where
- 7 sites in Brazil
- Volunteers
- 129 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal.
- Conditions
- Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
- Trial name
- NCT06339177
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus, COVID-19
Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
In December 2019 in the city of Wuhan in China, a series of patients with unclear pneumonia was noticed, some of whom have died of it.
- Conditions
- Coronavirus, COVID-19, SARS-CoV Infection, Respiratory Failure
- Trial name
- CYCOV (NCT04324528)
- Testing
- vv-ECMO + cytokine adsorption (Cytosorb adsorber), vv-ECMO only (no cytokine adsorption)
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Dr. Alexander Supady
Cytokine Storm
The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People
The effect of Weekly 50,000 IU vitamin D3 supplements on the serum levels of selected cytokines involved in cytokine storm of Covid-19; A randomized clinical trial in the Covid-19 uninfected people with vitamin D deficiency.
- Trial name
- NCT04476745
- Testing
- Vitamin D3
- Where
- Jordan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Applied Science Private University
CRS - Cytokine Release Syndrome, Myeloma
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.
- Trial name
- NCT07106671
- Testing
- Siltuximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
Cytokine Release Syndrome, ICANS
Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
This Phase I, prospective, single-arm clinical study aims to evaluate the efficacy and safety of adjunctive methylene blue (MB) in patients experiencing cytokine release syndrome (CRS) or immune effector cell-associated…
- Trial name
- NCT07169487
- Testing
- Methylene Blue
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cytokine Release Syndrome, Covid-19 Pneumonia
Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia
Tocilizumab (TCZ), interleukin-6 (IL-6), newly appeared as treatment of cytokine release syndrome (CRS) in patients with severe covid-19 associated pneumonia.
- Trial name
- NCT04873141
- Testing
- Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)
- Where
- Pakistan
- Volunteers
- 24 people
- Sponsor
- Shaheed Zulfiqar Ali Bhutto Medical University